Portland Investment Counsel Inc. Buys New Shares in Lantheus Holdings, Inc. $LNTH

Portland Investment Counsel Inc. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,000 shares of the medical equipment provider’s stock, valued at approximately $1,997,000. Lantheus comprises 0.6% of Portland Investment Counsel Inc.’s portfolio, making the stock its 25th largest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its position in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares during the period. Norges Bank acquired a new position in shares of Lantheus in the fourth quarter valued at about $76,197,000. Freestone Grove Partners LP raised its stake in shares of Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after purchasing an additional 594,088 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Lantheus by 686.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after purchasing an additional 522,678 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock opened at $99.97 on Monday. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86. The business’s 50-day moving average price is $104.08 and its 200 day moving average price is $90.52. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same period in the previous year, the company posted $1.57 earnings per share. Lantheus’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on LNTH. Citizens Jmp reiterated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Finally, Weiss Ratings cut shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.